Samenvatting
Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m2). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 1289-1294 |
Aantal pagina's | 6 |
Tijdschrift | Clinical Pharmacokinetics |
Volume | 55 |
Nummer van het tijdschrift | 10 |
DOI's | |
Status | Gepubliceerd - 1 okt. 2016 |
Extern gepubliceerd | Ja |